They are not in the headlines. They are in the trials. Twenty-eight people, one unusual mechanism, and a war chest most of biotech would envy.
It is mid-2026 inside a converted office on Montgomery Street. There is no marketing wall. No product launch countdown. There is a whiteboard with a molecule sketched in dry-erase, three open laptops, and a fridge that, depending on the week, holds either patient samples or birthday cake. The AltruBio team is small enough to fit around one long table - and it is on track to deliver mid-stage data on a drug that, if it works, will quietly change how doctors think about autoimmune disease.
This is the moment. Not a launch. Not an IPO. Just the slow, careful clinical work that biotech actually is when the press releases stop. AltruBio is what happens when a company stops trying to look big and starts trying to be right.
In cancer immunotherapy, the playbook is simple: find an immune checkpoint, block it, watch the T cells go to work. PD-1, CTLA-4 - household names in oncology.
AltruBio runs the playbook backwards. In autoimmune disease the immune system is the problem, not the lazy bystander. So the company is building agonist antibodies that turn a checkpoint on. The checkpoint is PSGL-1. The result, if the trials cooperate, is a calmer, better-regulated T cell population - the difference between yanking a fire alarm and resetting a thermostat.
Potency-enhanced, first-in-class anti-PSGL-1 antibody. Phase 2a in biologic-refractory ulcerative colitis. Global Phase 2b (ASCEND-UC2b) on deck.
Prior anti-PSGL-1 candidate with Phase 2a data across ulcerative colitis, psoriasis and psoriatic arthritis - plus Phase 1 work in acute graft-versus-host disease.
An antibody platform agonizing the PSGL-1 checkpoint to restore T-cell homeostasis. The thesis: heal the regulator, not the symptom.
An early-stage biotech with a cancer focus and a long road ahead.
Judy Chou, fresh out of Bayer Pharmaceuticals, joins as President & CEO. The company changes its name to AltruBio and pivots from oncology toward immune homeostasis.
ALTB-268 enters a Phase 2a exploratory biomarker study in biologic-refractory ulcerative colitis.
BVF Partners leads, with RA Capital, Cormorant, Soleus, Blackstone Multi-Asset Investing, and aMoon. Cumulative capital crosses $325M.
The Phase 2a readout is on the horizon. A Phase 2b is being designed. The team is still 28 people.
25+ years in drug development and biomanufacturing. Previously headed the global Biotech organization at Bayer Pharmaceuticals. Joined AltruBio in 2020 to run a near-bankrupt company - and has since raised close to $300M, repointed the science, and pushed two candidates into mid-stage clinical work. Also serves on the board of CIRM, California's stem cell agency.
Lead: BVF Partners. Co-investors: RA Capital, Cormorant, Soleus, Blackstone Multi-Asset Investing, aMoon, Delos Capital. Five of these funds rarely show up in the same round. They did here.
Ulcerative colitis already has a crowded shelf: Skyrizi, Rinvoq, Omvoh, etrasimod, the older anti-TNFs. Patients still cycle through them. They lose response. They relapse. "Biologic-refractory" is shorthand for a real, persistent, unsolved population.
That is the group AltruBio is studying. If ALTB-268 shows efficacy where existing biologics have run out, it stops being a niche bet and starts being something larger: evidence that immune checkpoint enhancement is a viable, distinct category. The same mechanism could read across to psoriasis, psoriatic arthritis, and graft-versus-host disease - all places where the earlier ALTB-168 already produced positive Phase 2a signals.
It is still a converted office. There is still a whiteboard. The fridge still does double duty. The team is still small enough to fit around one long table.
But the whiteboard has different math now. The molecule on it has moved through Phase 2a. Patients have taken it. A Phase 2b is being designed. The cap table is large enough to keep the lights on for years. The questions are no longer "can we survive?" - they are "does this work, and for whom, and how broadly?"
The same small office. A wildly different center of gravity. AltruBio did not get loud. It got useful. The difference, in biotech, is everything.